Genmab A/S (GMAB)
| Market Cap | 17.40B |
| Revenue (ttm) | 3.65B |
| Net Income (ttm) | 1.37B |
| Shares Out | 61.50M |
| EPS (ttm) | 21.62 |
| PE Ratio | 12.69 |
| Forward PE | 15.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,484,397 |
| Open | 28.27 |
| Previous Close | 28.61 |
| Day's Range | 27.82 - 28.35 |
| 52-Week Range | 17.24 - 28.75 |
| Beta | 0.80 |
| Analysts | Buy |
| Price Target | 37.60 (+35.16%) |
| Earnings Date | Nov 5, 2025 |
About GMAB
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no... [Read more]
Financial Performance
In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for GMAB stock is "Buy." The 12-month stock price target is $37.6, which is an increase of 35.16% from the latest price.
News
Genmab Transitioning To A Global Oncology Powerhouse: Why I Choose To Buy
Genmab is rated BUY due to strong royalty income, surging drug sales, and a robust late-stage oncology pipeline. GMAB's H1 2025 revenue rose 19%, driven by Darzalex royalties and rapid growth in self-...
Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff
Genmab A/S is leveraging its royalty-centric model and new ADCs like Epkinly to offset upcoming Darzalex patent expiry risks. Epkinly's strong Phase 3 data in follicular lymphoma positions GMAB for bl...
Genmab: A Matter Of Time
Genmab raised the full-year revenue and operating income guidance after strong Q2 results, driven by robust royalty streams and growing net sales of Epkinly and Tivdak. Genmab's maturing and expanding...
Genmab A/S (GMAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Genmab A/S (GMAB) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - Executive ...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; September 9, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; September 09, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,532 shares as a consequence of the exercise of employee warrants. The inc...
10 stocks to consider if you want alternatives to the expensive S&P 500
Stocks in developed economies outside the U.S. tend to trade at lower valuations. Some of the companies are expected to expand their businesses rapidly over the next two years.
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced updated results from the Phase 2 EPCORE® NHL-6 trial (NCT05451810) evaluating the safety and efficacy of investigational...
Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference
Media Release COPENHAGEN, Denmark; August 26, 2025 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and C hief F inancial O fficer Anthony Pagano will part...
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to rinatabart sesute...
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
Genmab A/S GMAB released results Thursday of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) versus R2 alone for adult patients wi...
Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript
Genmab A/S (GMAB) Q2 2025 Earnings Conference Call August 7, 2025 12:00 PM ET Company Participants Anthony Pagano - Executive VP & CFO Brad Bailey - Corporate Participant Jan G.J. van de Winkel - Co-F...
Genmab Announces Financial Results for the First Half of 2025
August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab a dvancing to earlier lines of therapy with the submission of a sBLA to the FDA for epc...
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced positive results of the Phase 3 EPCORE® FL-1 trial evaluating subcutaneous epcoritamab, a bispecific antibody, in combin...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025
Company Announcement Net sales of DARZALEX ® in the second quarter of 2025 totaled USD 3,539 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen ...
Genmab Announces Changes to its Executive Committee
Media Release COPENHAGEN, Denmark; July 1, 2025 Birgitte Stephensen, Executive Vice President and Chief Legal Officer to retire after 23 years with Genmab A/S Greg Mueller joins as new Executive Vice ...
Completion of Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; June 30, 2025 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2025. On March 25, 2025, Genmab announced t...
Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One
Genmab A/S is a high-margin, royalty-driven biotech with a robust pipeline and strong partnerships, notably with J&J, AbbVie, and Pfizer. Darzalex remains the key revenue driver, but patent protection...
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; June 23, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shar...
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bisp...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; June 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 3,320 restricted stock units and 3,636 warrants to empl...
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today new data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational...
Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference
Media Release COPENHAGEN, Denmark; May 27, 2025 Genmab A/S (Nasdaq: GMAB) announced today that its C hief F inancial O fficer Anthony Pagano will participate in a fireside chat at the 4 6 th Goldman ...